Skip to content

EXERT-BC Protein: Protein Supplementation to Improve Body Composition After Treatment for Breast Cancer

EXERT-BC Protein: Randomized Study of Protein Supplementation to Improve Body Composition Improvement During Hypertrophy Exercise After Treatment for Breast Cancer

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07704476
Enrollment
40
Registered
2026-07-15
Start date
2026-06-01
Completion date
2027-06-01
Last updated
2026-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Cancer

Keywords

Exercise, Resistance Training

Brief summary

In this study, the investigators hypothesize that a high dose of post-workout protein after each exercise session will have greater improvements in changes in body composition, including muscle mass and percent body fat versus a workout alone.

Interventions

DIETARY_SUPPLEMENTWhey protein (60 grams)

60 grams of whey protein

OTHERNo protein

0 grams of whey protein

Sponsors

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 89 Years
Healthy volunteers
No

Inclusion criteria

1. Age 20-89 years 2. Women prescribed exercise as a SOC 3. Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast 4. Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed. 5. Women with \> 3 months of resistance training experience under expert guidance by a CSCS 6. Must be able to read and understand English and consent for themselves.

Exclusion criteria

1. Any current treatment with cytotoxic chemotherapy for breast cancer 2. Inability to safely engage in group sessions of resistance training as deemed by study PI 3. Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training 4. Beta blocker or GLP-1 inhibitor medications 5. Pregnant women 6. Males 7. Lactose intolerance 8. Cow's milk or whey protein allergy

Design outcomes

Primary

MeasureTime frame
Determine changes in pounds of muscle and fat mass after each exercise regimenBaseline and at program completion (within 4 weeks of exercise completion)

Secondary

MeasureTime frameDescription
Determine changes in resting metabolic rate in calories per day at the completion of the exercise regimenBaseline and at program completion (within 4 weeks of exercise completion)
Determine changes in body composition at the completion of the exercise regimen, including body mass in pounds, fat mass in pounds, fat-free mass in pounds, % fat, and % fat-free massBaseline and at program completion (within 4 weeks of exercise completion)
Determine changes in Y-balance score at the completion of the exercise regimenBaseline and at program completion (within 4 weeks of exercise completion)Y-Balance score measures the length an individual can extend their foot. The larger the score the better the balance.
Functional Movement Screen (FMS) scores at the completion of the exercise regimenBaseline and at program completion (within 4 weeks of exercise completion)FMS measures movement patterns with scoring from 0 to 21. The large the score the better the mobility.
Determine changes in phase angle at the completion of the exercise regimenAt program completion (at 8 weeks)Phase angle measures the fluidity of cells and the larger the value the better.

Countries

United States

Contacts

CONTACTClinical Trials Contact
ctgov@ahn.org412-330-6151
PRINCIPAL_INVESTIGATORColin Champ, MD, CSCS

AHN Radiation Oncology

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 16, 2026